Fundraising Fox
Revalesio
Tacoma, US · Delaware corporation
Find your way into Revalesio
Sign up to see every warm intro you have to Revalesio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Revalesio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Revalesio is a clinical-stage pharmaceutical company developing mitochondrial-targeted therapies for stroke and neurodegenerative diseases. The company focuses on treatments that restore mitochondrial health to improve cellular recovery and protect neurons in acute brain injury and aging-related neurological decline.
Founders & leadership
Board
JN
JAMES NORDSTROMBoard director
CF
CHRIS FIBIGERBoard director
BV
BERT VAN DEN BERGHBoard director
JT
JANE TAYLORBoard director
MI
MATT IRELANDBoard director
MR
Marsha RussellBoard director
TA
TROY ALSTEADBoard director
LH
Lee HuntsmanBoard director
SW
SCOTT WALCHEKBoard director
Reported raises · per SEC filings
Form D private placements$92.7M disclosed across 5 rounds · 2014–2022
▶$38.9MraisedDec 2025 · 31 investors · PharmaceuticalsRule 506(b)
▶$38.9MraisedDec 2025 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JAMES NORDSTROMDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- CHRIS FIBIGERDirector
- BERT VAN DEN BERGHDirector
- JANE TAYLORDirector
- MATT IRELANDDirector
- Offering amount
- $40.3M
- Amount sold
- $38.9M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.4MraisedJul 2020 · 22 investors · PharmaceuticalsRule 506(b)
▶$20.4MraisedJul 2020 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LIAM GALLACHERDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- JANE TAYLORDirector
- MATT IRELANDDirector
- BERT VAN DEN BERGHDirector
- JAMES NORDSTROMDirector
- Offering amount
- $26.8M
- Amount sold
- $20.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJun 2018 · 6 investors · PharmaceuticalsRule 506(b)
▶$6MraisedJun 2018 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MATT IRELANDDirector
- JANE TAYLORDirector
- JEFFREY SMITHDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- JIM NORDSTROMDirector
- Offering amount
- $12M
- Amount sold
- $6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedJul 2016 · 11 investors · BiotechnologyRule 506(b)
▶$14MraisedJul 2016 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MARSHA RUSSELLDirector
- BERT VAN DEN BERGHExecutive Officer
- ERIC RUSSELLDirector
- TROY ALSTEADDirector
- GREG ARCHAMBEAUExecutive Officer
- BRUCE BUSKIRKExecutive Officer
- LEE HUNTSMANDirector
- SCOTT WALCHEKDirector
- PATRICK CARUANADirector
- Offering amount
- $14M
- Amount sold
- $14M
- Minimum investment
- $27.7K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedMay 2014 · 3 investors · BiotechnologyRule 506(b)
▶$13.5MraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric RussellExecutive Officer, Director
- Lee HuntsmanDirector
- Marsha RussellDirector
- Scott WalcheckDirector
- Patrick CaruanaDirector
- Karl BandlienDirector
- Offering amount
- $40M
- Amount sold
- $13.5M
- Minimum investment
- $500K
- Proceeds to insiders
- $200K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Revalia Bio, Inc.Revalia Bio uses AI to convert donated human organs and tissues into multi-modal biological datasets and decision-ready insights for drug and device development. It operates an Organ ICU facility and works with organ procurement organizations and healthcare institutions to serve pharma, biotech, and medical device companies.
VesalioVesalio develops stroke treatment technology, specifically devices and systems for endovascular neurosurgical interventions to treat acute ischemic and hemorrhagic stroke. The company serves hospitals and neurosurgeons seeking advanced treatment options.
Imperative Care IncImperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey. The company focuses on devices and solutions for patients suffering from devastating vascular conditions.
Renovo RxRenovoRx is a life sciences company developing targeted drug delivery for cancer treatment, including its TAMP therapy approach. It operates as a publicly listed biopharmaceutical/medical device company focused on oncology.
Vesalius TherapeuticsVesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as Revalesio.
In the news
Frequently asked questions
- What does Revalesio do?
- Revalesio is a clinical-stage pharmaceutical company developing mitochondrial-targeted therapies for stroke and neurodegenerative diseases. The company focuses on treatments that restore mitochondrial health to improve cellular recovery and protect neurons in acute brain injury and aging-related neurological decline.
- How much funding has Revalesio raised?
- Revalesio has disclosed $92.7M raised across 5 rounds.
- Where is Revalesio headquartered?
- Revalesio is headquartered in Tacoma, US.